PR Newswire BiotechOriginal article
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
Phase 2approvedziresovirPositive
AI Analysis
Summary
ArkBio announced FDA approval for ziresovir (AK0529), an RSV antiviral drug, to proceed into Phase II clinical trials in severely ill RSV-infected infant patients.
Clinical Trial Data
Phase
Phase II
Outcome Details
FDA approved ziresovir for Phase II clinical trial in severely ill RSV infected infant patients
Importance:6/10
Sentiment:
0.80
RSVantiviralFDA approvalpediatricclinical trial
Read the original article
Published by PR Newswire Biotech on August 14, 2026 10:08 AM